genomiQa and Max Kelsen have teamed up to integrate genomics and artificial intelligence (AI).
This innovative flagship project aims to make immunotherapy more cost effective. Integrating genomics and AI signals the future of precision medicine and will help to predict the response of immunotherapy for treating cancer.
Max Kelsen produces leading research in applying AI to real-world problems. For the past three years it has partnered with Australian enterprises, governments and research organisations.
This $9.1 million project—which is partially funded by a Federal Government CRC-P $2.6 million grant—shows our commitment to accelerating research to improve patient outcomes within the next three years.
Other key players in this project are: